Results 181 to 190 of about 8,055 (251)

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8946-8954, October 2026.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications. [PDF]

Obes Sci Pract
Chao AM, Asante R, Sersah ME, Jahangir UA, Peary A, Kudaya D.   +5 more
europepmc   +1 more source

The longevity dividend: Why governments and markets must catch up

Experimental Physiology, EarlyView.
Nikodem Grzesiak, Serena Kern‐Libera, Richard Faragher, Annalisa Jenkins, Guy Coughlan, Damian Miles Bailey, Carina Kern   +6 more
wiley   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9403-9411, October 2026.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.

J Clin Endocrinol Metab
Mandour MO, Stears A, Van Der Klaauw A, Flanagan C, Gaff L, Jenkins C, Savage DB.   +6 more
europepmc   +1 more source

Sleep Health and Obesity. [PDF]

JAMA
Malhotra A, Kumar AJ, Mesarwi OA.
europepmc   +1 more source

Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9166-9177, October 2026.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety, and tolerability of the Omnipod 5 hybrid closed‐loop system in adults with type 1 diabetes (T1D) with a novel focus on cardiometabolic markers alongside diabetic eye disease and renal function. Methods A single‐centre, retrospective analysis of adults with T1D using Omnipod 5 was conducted.
Eleanor McNally, Iona Goodman, Rebecca Morris, John Maliekkal, Dalha Saeed, Hao Wei Tan, Simon Berry, Jackie Elliott, Ahmed Iqbal   +8 more
wiley   +1 more source

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9317-9325, October 2026.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +1 more source

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study. [PDF]

Front Endocrinol (Lausanne)
Galasso M, Verde L, Patrone R, Ragozzino G, Annunziata G, Colao A, Barrea L, Muscogiuri G.   +7 more
europepmc   +1 more source